CPSE:NOVO BPharmaceuticals
Can Novo Nordisk (CPSE:NOVO B) Stay Cheap As GLP 1 Access Expands?
Novo Nordisk stock has pulled back sharply over the past year, yet the shares still screen as undervalued on earnings. This sets up a clear tension between recent price weakness and what the valuation checks suggest.
Over the past 5 years, Novo Nordisk has returned 33.4%, which still points to a solid long term gain despite a tough recent stretch.
Expectations around GLP-1 weight loss and diabetes treatments, helped by moves such as Medicare’s GLP-1 Bridge program, can support higher...